1cBio Receives Proceeds After BioMarin Acquires Alesta

San Francisco, California, United States, October 14, 2026

BioMarin Acquisition Strengthens Rare Disease Pipeline

The acquisition of Alesta Therapeutics represents a strategic expansion of BioMarin’s portfolio of treatments for rare genetic conditions. Under the transaction announced in August 2026, BioMarin agreed to pay $275 million upfront, with the potential for up to an additional $215 million in development and regulatory milestone payments. The transaction was completed in September, following the separation of Alesta’s non-ALE1 assets into a new entity. ALE1 was the principal clinical-stage asset included in the acquisition. Its development aligns with BioMarin’s focus on genetically defined diseases and conditions where existing treatment options may not adequately address patients’ needs. The company has established experience in rare-disease drug development and commercializing specialized therapies for patients with significant unmet medical needs. For 1cBio, the completed transaction marks an important milestone in the development journey of a program it initially discovered and advanced. By licensing ALE1 to Alesta, 1cBio enabled the candidate to progress through further development while retaining the possibility of future financial returns linked to its clinical, regulatory and commercial success. The acquisition also demonstrates how biotechnology companies can create value by identifying promising drug candidates, establishing an initial development strategy and partnering with organizations that have the resources to advance clinical programs toward potential commercialization.

ALE1 Targets Hypophosphatasia and Bone Health

ALE1 is an orally active investigational small molecule designed to treat hypophosphatasia, a rare inherited disorder caused by mutations in the ALPL gene. These mutations impair the activity of tissue-nonspecific alkaline phosphatase, an enzyme essential for normal bone and tooth mineralization. The resulting enzyme deficiency can lead to abnormal accumulation of inorganic pyrophosphate (PPi), a substance that inhibits the mineralization process. Patients may experience recurrent fractures, bone pain, muscle weakness, fatigue, premature loss of primary or permanent teeth, and other complications. Disease severity varies widely, ranging from severe forms presenting early in life to manifestations that become apparent during adulthood. ALE1 is designed to target PPi, a central disease-associated metabolite, with the aim of correcting an underlying biochemical disturbance rather than simply managing individual symptoms. Its oral administration may offer a convenient treatment approach if clinical studies establish an acceptable safety profile and meaningful therapeutic benefit. The candidate is currently being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and adults with HPP. These early-stage studies are intended to characterize how the investigational drug behaves in the body and provide evidence to guide subsequent development. ALE1 remains investigational, and its safety and effectiveness have not yet been established for routine clinical use. Further clinical research and regulatory review will be necessary before it can become an approved treatment option.

1cBio Retains Future Milestone and Royalty Rights

Following BioMarin’s acquisition of Alesta, 1cBio retains a continuing economic interest in ALE1 under the licensing agreement assumed by the acquiring company. This includes potential payments tied to development progress, regulatory milestones and commercial performance, as well as tiered royalties on worldwide sales if the product reaches commercialization. The financial terms of the proceeds received by 1cBio were not disclosed in the announcement. Future payments will depend on the applicable contractual terms and achievement of the specified milestones. The transaction highlights the importance of intellectual property, early drug discovery and licensing agreements in the biotechnology sector. For smaller research-focused companies, partnering with larger pharmaceutical organizations can provide a pathway for advancing promising candidates while preserving potential long-term financial participation. For BioMarin, ALE1 offers an opportunity to expand its rare-disease development pipeline with a potential oral therapy for HPP. For 1cBio, the completed acquisition provides recognition of its early research and preserves the possibility of future economic returns as the candidate advances. Ultimately, ALE1’s clinical progress will determine its potential value for patients and the companies involved. Continued evaluation of safety, biological activity and clinical benefit will be essential in establishing whether this investigational therapy can become a meaningful new option for people living with hypophosphatasia.

Source: 1cBio, BioMarin Pharmaceutical press release